What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M, Roubaud G, Fromont G, Gauthé M, Beauval JB, Barret E, Brureau L, Créhange G, Dariane C, Fiard G, Mathieu R, Ruffion A, Rouprêt M, Renard-Penna R, Sargos P, Ploussard G; Prostate Cancer Committee of the French Association of Urology.
Baboudjian M, et al. Among authors: sargos p.
World J Urol. 2023 Aug;41(8):2033-2041. doi: 10.1007/s00345-022-04239-1. Epub 2022 Dec 9.
World J Urol. 2023.
PMID: 36484817
Review.